Long-term follow-up after gene therapy treatment
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study is a long-term follow-up for people who previously received a gene therapy treatment called zamtocabtagene autoleucel in a Miltenyi Biomedicine-sponsored clinical study. It helps researchers monitor your health over time after the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have already received a treatment called zamtocabtagene autoleucel in a Miltenyi Biomedicine-sponsored study in North America.
- You have not withdrawn your consent to be followed, and you are not considered lost to follow-up.
- You are willing to provide written consent to participate in this long-term follow-up study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks in with people who already received CAR-T therapy to learn how they’re doing over time. It may help doctors understand the long-term benefits and side effects of CAR-T for future patients.
This study is for people who have already received a special kind of cell therapy that involved modifying their genes. The purpose is to keep track of their health over a longer period of time to see how they are doing after the treatment.
This study is a long-term follow-up for people who have already received a cell or gene therapy in a previous AstraZeneca trial. It helps researchers monitor your health over time to make sure the therapy is safe and effective.
This study follows up with people who previously received a gene therapy product from A2 Biotherapeutics in an earlier trial. The goal is to monitor their health over time and check for any long-term effects.
This study follows patients who have had gene-modified T-cell therapy to track their health over time. It does not test a new treatment but helps doctors understand long-term effects.
This study checks how people are doing years after receiving a specific company’s gene-edited immune cell treatment. It helps researchers learn about long-term safety and health outcomes.
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.